[{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"CYR-064","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BLU-808","moa":"c-Kit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"LYR-220","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Public Offering","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Series C Financing","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Med-El Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Med-El Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Med-El Corporation"},{"orgOrder":0,"company":"Auditus","sponsor":"Oblato","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Acetylcysteine","moa":"||Glutathione synthase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Auditus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Auditus \/ Oblato","highestDevelopmentStatusID":"8","companyTruncated":"Auditus \/ Oblato"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | ALK | Regeneron Pharmaceuticals | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | ALK | Regeneron Pharmaceuticals | PPD | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | ALK | Regeneron Pharmaceuticals | PPD | Rho, Inc"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acousia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acousia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"muscarinic receptor agonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"muscarinic receptor agonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"muscarinic receptor agonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"muscarinic receptor agonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"OTO-313","moa":"NMDA receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Series A Financing","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Remiges Ventures"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Series B Financing","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ DeepWork Capital"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Agreement","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Kyorin Pharmaceutical"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Kevin Winthrop","sponsor":"National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orc-13661","moa":"Potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Kevin Winthrop","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kevin Winthrop \/ National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at","highestDevelopmentStatusID":"8","companyTruncated":"Kevin Winthrop \/ National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"University of Texas System | Gateway Biotechnology | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Washington University School of Medicine \/ University of Texas System | Gateway Biotechnology | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ University of Texas System | Gateway Biotechnology | US Department of Defense"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"US Department of Defense | University of Texas System | Gateway Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Washington University School of Medicine \/ US Department of Defense | University of Texas System | Gateway Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ US Department of Defense | University of Texas System | Gateway Biotechnology"},{"orgOrder":0,"company":"AudioCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AC102","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AudioCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AudioCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AudioCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AudioCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AC102","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AudioCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AudioCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AudioCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Elizabeth J Franzmann","sponsor":"Aveta Biomics","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"APG-157","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Elizabeth J Franzmann","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elizabeth J Franzmann \/ Aveta Biomics","highestDevelopmentStatusID":"8","companyTruncated":"Elizabeth J Franzmann \/ Aveta Biomics"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DPPC","moa":"||Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Novus Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DPPC","moa":"||Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Novus Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FGF-2","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frequency Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Audion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY3056480","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Audion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Audion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Audion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQC2731","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQH2722","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"}]

Find Drugs for Otolaryngology (Ear, Nose, Throat) in Phase II Clinical Development

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Nasal Polyps.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          August 12, 2013

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : BLU-808 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinoconjunctivitis, Allergic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 10, 2025

                          Lead Product(s) : BLU-808

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : CYR-064 (theophylline) is a patent-protected, intranasal formulation of a broad-spectrum PDE inhibitor designed to enhance olfactory neuron excitability and restore the sense of smell.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          April 10, 2025

                          Lead Product(s) : Theophylline

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : SENS-401 (R-azasetron besylate) is a 5-HT3 receptor antagonist, orally available small molecule, which is under clinical development for the treatment of Cisplatin-Induced Ototoxicity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 07, 2025

                          Lead Product(s) : R-Azasetron Besylate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064. It is being evaluated for the treatment of hyposmia.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Undisclosed

                          February 18, 2025

                          Lead Product(s) : Theophylline

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Kyorin Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : CYR-064 (theophylline) is an intranasal spray works by inhibiting PDE3/4, currently being evaluated for the treatment of hyposmia in parkinson patients.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          February 04, 2025

                          Lead Product(s) : Theophylline

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : ACOU085 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cisplatin-induced Hearing Loss.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 25, 2024

                          Lead Product(s) : ACOU085

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : SENS-401 (R-azasetron besylate) is a 5-HT3 receptor antagonist, orally available small molecule, which is under clinical development for the treatment of Cisplatin-Induced Ototoxicity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 22, 2024

                          Lead Product(s) : R-Azasetron Besylate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 15, 2024

                          Lead Product(s) : R-Azasetron Besylate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Ebselen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hearing Loss.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 01, 2024

                          Lead Product(s) : Ebselen

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Med-El Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank